RUNX1 and cancer: Biological variables associated to a high risk of progression included CIP2A levels (165), the expression levels of the polycomb group BMI1 gene (166), the activation of beta-catenin (167), specific gene signatures (168), and mutations in cancer-associated genes such as ASXL1, IKZF1, RUNX1, SETD1B, GATA2, MLL, and UBE2A (169).